SGMT
Sagimet Biosciences Inc.
$6.43
-0.07
(-1.08%)
Mkt Cap
209.50M
Volume
747,304
52W Range
4.5-11.41
Sector
Healthcare
Beta
3.44
EPS (TTM)
-1.35
P/E Ratio
-3.75
Revenue (TTM)
0
Rev Growth (5Y)
N/A
EPS Growth (5Y)
N/A
Company Description
Sagimet Biosciences Inc. is a biopharmaceutical company with drug candidates in clinical trials, specializing in developing therapies that target fatty acid synthase (FASN) inhibition. These treatments are engineered to combat medical conditions stemming from impaired lipid metabolism pathways. Its primary investigational compound, Denifanstat, is a FASN inhibitor currently being evaluated for nonalcoholic steatohepatitis (NASH) and acne. Additionally, Sagimet is advancing TVB-3567, another FASN inhibitor, which targets various forms of cancer. Founded in 2006, the company's main operations are located in San Mateo, California. It was formerly recognized as 3-V Biosciences, Inc. until it rebranded to Sagimet Biosciences Inc. in August 2019.
Track Record
Showing latest 4 periods • Swipe for more
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 2.00M | 0 | 0 | 0 | 0 |
| Net Income | (51.04M) | (45.57M) | (27.88M) | (30.50M) | (24.44M) | (11.37M) | (14.26M) |
| EPS | -1.58 | -1.45 | -1.53 | -1.38 | -1.10 | -0.51 | -0.64 |
| Free Cash Flow | (45.65M) | (42.44M) | (23.77M) | (24.49M) | (21.71M) | (10.42M) | (10.55M) |
| FCF / Share | -1.41 | -1.35 | -1.31 | -1.10 | -0.98 | -0.47 | -0.48 |
| Operating CF | (45.65M) | (42.44M) | (23.77M) | (24.49M) | (21.71M) | (10.42M) | (10.55M) |
| Total Assets | 116.48M | 160.26M | 96.72M | 33.03M | 59.03M | 68.96M | 11.16M |
| Total Debt | 78,000 | 78,000 | 65,000 | 211,000 | 348,000 | 210,000 | 341,000 |
| Cash & Equiv | 35.02M | 75.84M | 75.14M | 158,000 | 56.73M | 68.70M | 10.21M |
| Book Value | 111.38M | 155.81M | 91.06M | (186.95M) | (158.26M) | (135.91M) | (125.31M) |
| Return on Equity | -0.46 | -0.29 | -0.31 | N/A | N/A | N/A | N/A |
| Metric | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2.00M | 0 |
| Net Income | (10.65M) | (9.57M) | (12.91M) | (10.39M) | (18.18M) | (16.20M) | (14.62M) | (8.12M) | (6.63M) | (8.15M) | (6.35M) | (6.79M) |
| EPS | -0.33 | -0.30 | -0.40 | -0.32 | -0.56 | -0.50 | -0.45 | -0.25 | -0.23 | -0.45 | -0.35 | -0.31 |
| Free Cash Flow | (8.61M) | (11.83M) | (10.18M) | (9.10M) | (14.54M) | (11.02M) | (19.57M) | (5.63M) | (6.21M) | (7.08M) | (3.88M) | (5.72M) |
| FCF / Share | -0.26 | -0.37 | -0.31 | -0.28 | -0.45 | -0.34 | -0.61 | -0.18 | -0.21 | -0.39 | -0.21 | -0.26 |
| Operating CF | (8.61M) | (11.83M) | (10.18M) | (9.10M) | (14.54M) | (11.02M) | (19.57M) | (5.63M) | (6.21M) | (7.08M) | (3.88M) | (5.72M) |
| Total Assets | 107.75M | 116.48M | 128.40M | 137.41M | 146.17M | 160.26M | 174.78M | 189.02M | 194.53M | 96.72M | 102.92M | 21.50M |
| Total Debt | 39,000 | 78,000 | 115,000 | 152,000 | 39,000 | 78,000 | 116,000 | 153,000 | 26,000 | 65,000 | 103,000 | 140,000 |
| Cash & Equiv | 36.63M | 35.02M | 32.50M | 42.33M | 64.72M | 75.84M | 77.01M | 95.96M | 176.78M | 75.14M | 101.84M | 18.51M |
| Book Value | 102.46M | 111.38M | 119.25M | 130.16M | 138.99M | 155.81M | 170.68M | 183.29M | 190.02M | 91.06M | 97.88M | (198.41M) |
| Return on Equity | -0.10 | -0.09 | -0.11 | -0.08 | -0.13 | -0.10 | -0.09 | -0.04 | -0.03 | -0.09 | -0.06 | N/A |
SGMT News
Here's Why Sagimet Biosciences Inc. (SGMT) Could be Great Choice for a Bottom Fisher
Sagimet Biosciences Presents Two Posters at EASL 2026 on Denifanstat/Resmetirom Combination in MASH
Wall Street Analysts Believe Sagimet Biosciences Inc. (SGMT) Could Rally 298.5%: Here's is How to Trade
Sagimet Biosciences: Making The Bull Case For Differentiated Denifanstat
Sagimet Biosciences to Participate in the H.C. Wainwright 4th Annual BioConnect Investor Conference at NASDAQ
Sagimet Biosciences Reports First Quarter 2026 Financial Results and Provides Corporate Updates
Sagimet Biosciences Reports First Quarter 2026 Financial Results and Provides Corporate Updates
Sagimet Biosciences to Present Mechanism of Action Data for its FASN Inhibitors at the Society for Investigative Dermatology in Chicago
Sagimet Biosciences Inc. (SGMT) is a Great Momentum Stock: Should You Buy?
Does Sagimet Biosciences Inc. (SGMT) Have the Potential to Rally 241.77% as Wall Street Analysts Expect?